Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

David Einhorn’s Greenlight Down Around 2% Through February

One of the ways of following David Einhorn’s performance is through the disclosures made by Greenlight Capital Re (GLRE). Greenlight Re posted on its website that it lost 0.8% in February and 1.4% through the end of February. However, this doesn’t mean that Einhorn’s flagship fund lost 1.4% so far in 2011. Insider Monkey, your source for free insider trading data, compared GLRE’s investment returns and Einhorn’s performance. In 2010, Einhorn’s flagship fund returned 15.9% but GLRE’s investment returns were only 11%. In 2009, Einhorn returned around close to 37%, but GLRE’s investments gained 32.1%. In 2008, GLRE lost 17.6% and Einhorn‘s flagship fund lost more than 20%.

David Einhorn GREENLIGHT CAPITAL

Greenlight Capital Re probably keeps a certain percentage of its funds in cash or low-risk debt instruments. As a result, GLRE underperforms Einhorn in good years and outperforms in bad years. Since this years performance is a loss of 1.4% for GLRE, this implies that David Einhorn’s flagship fund potentially lost around 2% through February.

At the end of December, Greenlight’s largest long positions were Arkema, Ensco, gold, Pfizer, and Vodafone Group. At the end of February GLRE reported that the largest disclosed long positions in the investment portfolio were Cardinal Health, Carefusion, Ensco, gold, Pfizer and Vodafone Group. Arkema lost around 2% through February, whereas Carefusion gained around 9%. Einhorn had $344 Million of Carefusion at the end of 2010. The Arkema position was at least $406 Million. This means either Einhorn reduced his Arkema holdings or added more Carefusion shares.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...